Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Akeso, Inc. has announced a new Phase II clinical study titled A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination With Lenvatinib Versus Lenvatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab. The study aims to evaluate the efficacy and safety of AK104 combined with lenvatinib compared to lenvatinib alone in patients with advanced hepatocellular carcinoma (HCC) who have not responded to first-line treatments.
The study tests two interventions: AK104, a biological agent administered intravenously, combined with lenvatinib, an oral drug, against lenvatinib alone. The combination aims to enhance treatment effectiveness for HCC patients.
This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment outcomes. The open-label design allows all participants and researchers to know which treatment is being administered.
The study is not yet recruiting as of the last update on May 15, 2025. It was first submitted on the same date, with no results yet available. These dates are crucial for tracking the study’s progress and potential availability of results.
For investors, this study could signal potential growth for Akeso, Inc. if the combination therapy proves successful, potentially impacting stock performance positively. The development also positions Akeso in a competitive stance within the oncology treatment market, especially against other HCC therapies.
The study is ongoing, with further details accessible on the ClinicalTrials portal.